export interface DrugApproval {
  approvalMonth: string;
  approvalDate: string;
  ndaBlaNumber: string;
  applicationNo: string;
  applicationType: string;
  brandName: string;
  activeIngredient: string;
  sponsor: string;
  indicationFull: string;
  therapeuticArea: string;
  isOncology: boolean;
  isBiosimilar: boolean;
  isNovelDrug: boolean;
  isOrphanDrug: boolean;
  approvalType: string;
  notes: string;
  fdaUrl?: string;
}

export const fdaApprovals: DrugApproval[] = [
  // ===== 2026년 1월 승인 =====
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-27",
    ndaBlaNumber: "BLA 761145",
    applicationNo: "761145",
    applicationType: "BLA",
    brandName: "DARZALEX FASPRO",
    activeIngredient: "daratumumab and hyaluronidase-fihj",
    sponsor: "Janssen Biotech",
    indicationFull: "자가 조혈모세포이식 부적격 신규 진단 다발골수종 성인 환자의 bortezomib, lenalidomide, dexamethasone (VRd) 병용요법",
    therapeuticArea: "항암제 - 다발골수종",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "정규승인",
    notes: "변경승인 - 이식 부적격 NDMM VRd 병용요법 적응증 추가",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-newly",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-12",
    ndaBlaNumber: "BLA 761948",
    applicationNo: "761948",
    applicationType: "BLA",
    brandName: "ZYCUBO",
    activeIngredient: "copper histidinate",
    sponsor: "Sentynl Therapeutics",
    indicationFull: "Menkes disease 소아 환자의 구리 보충 치료",
    therapeuticArea: "소아과 - 대사질환",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: true,
    approvalType: "정규승인",
    notes: "FDA 최초 승인 Menkes disease 치료제, Breakthrough Therapy 및 Rare Pediatric Disease 지정",
    fdaUrl: "https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-children-menkes-disease",
  },
  // ===== 2025년 12월 승인 =====
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-05",
    ndaBlaNumber: "BLA 125486",
    applicationNo: "125486",
    applicationType: "BLA",
    brandName: "BREYANZI",
    activeIngredient: "lisocabtagene maraleucel",
    sponsor: "Bristol Myers Squibb",
    indicationFull: "이전에 최소 2회 이상의 전신 치료를 받은 재발성 또는 불응성 변연부 림프종(MZL) 성인 환자 치료",
    therapeuticArea: "항암제 - 림프종",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "정규승인",
    notes: "변경승인 - 변연부 림프종 적응증 확대",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-marginal-zone-lymphoma",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-11",
    ndaBlaNumber: "BLA 761145",
    applicationNo: "761145",
    applicationType: "BLA",
    brandName: "DARZALEX FASPRO",
    activeIngredient: "daratumumab and hyaluronidase-fihj",
    sponsor: "Janssen Biotech",
    indicationFull: "고위험 무증상 다발골수종 성인 환자의 단독요법 치료",
    therapeuticArea: "항암제 - 다발골수종",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "정규승인",
    notes: "변경승인 - 무증상 다발골수종 신규 적응증",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-high-risk-smoldering-multiple-myeloma",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-12",
    ndaBlaNumber: "NDA 217500",
    applicationNo: "217500",
    applicationType: "NDA",
    brandName: "AKEEGA",
    activeIngredient: "niraparib and abiraterone acetate",
    sponsor: "Janssen Biotech",
    indicationFull: "BRCA2 변이 전이성 거세민감성 전립선암(mCSPC) 성인 환자 치료를 위한 프레드니손 병용요법",
    therapeuticArea: "항암제 - 전립선암",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    notes: "거세민감성 전립선암 최초 PARP 억제제",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-brca2-mutated-metastatic-castration",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-17",
    ndaBlaNumber: "BLA 761139",
    applicationNo: "761139",
    applicationType: "BLA",
    brandName: "ENHERTU",
    activeIngredient: "fam-trastuzumab deruxtecan-nxki",
    sponsor: "Daiichi Sankyo/AstraZeneca",
    indicationFull: "HER2 양성 절제불가능 또는 전이성 유방암 성인 환자의 1차 치료를 위한 pertuzumab 병용요법",
    therapeuticArea: "항암제 - 유방암",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    notes: "변경승인 - pertuzumab 병용 1차 치료",
    fdaUrl: "https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-fam-trastuzumab-deruxtecan-nxki-pertuzumab-unresectable-or-metastatic-her2-positive",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-17",
    ndaBlaNumber: "BLA 761385",
    applicationNo: "761385",
    applicationType: "BLA",
    brandName: "RYBREVANT FASPRO",
    activeIngredient: "amivantamab and hyaluronidase-lpuj",
    sponsor: "Johnson & Johnson",
    indicationFull: "EGFR 변이 비소세포폐암 성인 환자의 피하주사 제형 치료",
    therapeuticArea: "항암제 - 폐암",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "정규승인",
    notes: "변경승인 - 피하주사 제형 추가",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-lpuj-egfr-mutated-non-small-cell-lung-cancer",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-19",
    ndaBlaNumber: "NDA 209115",
    applicationNo: "209115",
    applicationType: "NDA",
    brandName: "RUBRACA",
    activeIngredient: "rucaparib",
    sponsor: "Clovis Oncology",
    indicationFull: "BRCA 변이 전이성 거세저항성 전립선암(mCRPC) 성인 환자 치료",
    therapeuticArea: "항암제 - 전립선암",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "정규승인",
    notes: "변경승인 - mCRPC 적응증 추가 (신속승인→정규승인 전환)",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-rucaparib-metastatic-castration-resistant-prostate-cancer",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-19",
    ndaBlaNumber: "BLA 761689",
    applicationNo: "761689",
    applicationType: "BLA",
    brandName: "OZILTUS",
    activeIngredient: "denosumab-mobz",
    sponsor: "Amneal Pharmaceuticals",
    indicationFull: "다발골수종 또는 고형암 골전이 환자의 골격 관련 사건 예방, 골거대세포종 치료, 악성종양 고칼슘혈증 치료",
    therapeuticArea: "항암제 - 골전이",
    isOncology: true,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    notes: "Xgeva (denosumab) 바이오시밀러",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-denosumab-mobz-biosimilar-xgeva",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-22",
    ndaBlaNumber: "BLA 761333",
    applicationNo: "761333",
    applicationType: "BLA",
    brandName: "LUNSUMIO VELO",
    activeIngredient: "mosunetuzumab-axgb",
    sponsor: "Genentech",
    indicationFull: "재발성 또는 불응성 여포성 림프종 성인 환자의 피하주사 제형 치료",
    therapeuticArea: "항암제 - 림프종",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "정규승인",
    notes: "변경승인 - 피하주사 제형 추가",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mosunetuzumab-axgb-subcutaneous-relapsed-or-refractory-follicular-lymphoma",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-03",
    ndaBlaNumber: "BLA 761544",
    applicationNo: "761544",
    applicationType: "BLA",
    brandName: "AVANCE",
    activeIngredient: "acellular nerve allograft-arwx",
    sponsor: "Axogen",
    indicationFull: "말초신경 복구를 위한 무세포 신경 동종이식",
    therapeuticArea: "신경과 - 신경복구",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: false,
    approvalType: "정규승인",
    notes: "FDA 최초 승인 무세포 신경 동종이식",
    fdaUrl: "https://www.fda.gov/vaccines-blood-biologics/tissue-tissue-products/avance-nerve-graft",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-09",
    ndaBlaNumber: "BLA 125832",
    applicationNo: "125832",
    applicationType: "BLA",
    brandName: "WASKYRA",
    activeIngredient: "beremagene geparvorepvec",
    sponsor: "Sobi",
    indicationFull: "Wiskott-Aldrich 증후군 소아 환자의 유전자 치료",
    therapeuticArea: "면역학 - 유전자치료",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: true,
    approvalType: "정규승인",
    notes: "FDA 최초 승인 WAS 유전자 치료",
    fdaUrl: "https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/waskyra-beremagene-geparvorepvec",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-12",
    ndaBlaNumber: "NDA 218571",
    applicationNo: "218571",
    applicationType: "NDA",
    brandName: "CARDAMYST",
    activeIngredient: "etripamil",
    sponsor: "Milestone Pharmaceuticals",
    indicationFull: "성인 발작성 상심실성 빈맥(PSVT) 치료를 위한 비강 스프레이",
    therapeuticArea: "심장내과 - 부정맥",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: false,
    approvalType: "정규승인",
    notes: "FDA 최초 승인 PSVT 비강 스프레이",
    fdaUrl: "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-type-abnormally-fast-heart-rhythm",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-12",
    ndaBlaNumber: "NDA 219491",
    applicationNo: "219491",
    applicationType: "NDA",
    brandName: "NUZOLVENCE",
    activeIngredient: "zoliflodacin",
    sponsor: "Qpex Biopharma",
    indicationFull: "성인 임질 치료를 위한 경구용 항생제",
    therapeuticArea: "감염내과 - 성매개감염병",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: false,
    approvalType: "정규승인",
    notes: "FDA 최초 승인 spiropyrimidinetrione 계열 항생제",
    fdaUrl: "https://www.fda.gov/news-events/press-announcements/fda-approves-two-oral-therapies-treat-gonorrhea",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-16",
    ndaBlaNumber: "BLA 761458",
    applicationNo: "761458",
    applicationType: "BLA",
    brandName: "EXDENSUR",
    activeIngredient: "depemokimab-ulaa",
    sponsor: "GSK",
    indicationFull: "호산구 표현형 중증 천식 성인 환자 치료를 위한 장기작용 IL-5 길항제",
    therapeuticArea: "호흡기내과 - 천식",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: false,
    approvalType: "정규승인",
    notes: "FDA 최초 승인 장기작용 IL-5 길항제",
    fdaUrl: "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-maintenance-treatment-severe-asthma",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-18",
    ndaBlaNumber: "BLA 761702",
    applicationNo: "761702",
    applicationType: "BLA",
    brandName: "NUFYMCO",
    activeIngredient: "ranibizumab-leyk",
    sponsor: "Formycon",
    indicationFull: "황반변성, 황반부종, 당뇨망막병증, 근시성 맥락막신생혈관 치료",
    therapeuticArea: "안과",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    notes: "Lucentis (ranibizumab) 상호교환가능 바이오시밀러",
    fdaUrl: "https://www.fda.gov/drugs/biosimilars/fda-approves-ranibizumab-leyk-interchangeable-biosimilar-lucentis",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-19",
    ndaBlaNumber: "NDA 219083",
    applicationNo: "219083",
    applicationType: "NDA",
    brandName: "MYQORZO",
    activeIngredient: "aficamten",
    sponsor: "Cytokinetics",
    indicationFull: "증상이 있는 폐쇄성 비대성 심근병증 성인 환자의 기능적 능력 및 증상 개선",
    therapeuticArea: "심장내과 - 심근병증",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: true,
    approvalType: "정규승인",
    notes: "FDA 최초 승인 심근 억제제",
    fdaUrl: "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-improve-functional-capacity-and-symptoms-adults-rare-inherited-heart-condition",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-19",
    ndaBlaNumber: "BLA 761688",
    applicationNo: "761688",
    applicationType: "BLA",
    brandName: "BONCRESA",
    activeIngredient: "denosumab-mobz",
    sponsor: "Amneal Pharmaceuticals",
    indicationFull: "골다공증, 골량감소, 골절위험 증가 환자 치료",
    therapeuticArea: "내분비내과 - 골다공증",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    notes: "Prolia (denosumab) 바이오시밀러",
    fdaUrl: "https://www.fda.gov/drugs/biosimilars/fda-approves-denosumab-mobz-biosimilar-prolia",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-23",
    ndaBlaNumber: "NDA 219234",
    applicationNo: "219234",
    applicationType: "NDA",
    brandName: "AQVESME",
    activeIngredient: "mitapivat",
    sponsor: "Agios Pharmaceuticals",
    indicationFull: "알파-지중해빈혈 또는 베타-지중해빈혈 성인 환자의 빈혈 치료",
    therapeuticArea: "혈액내과 - 지중해빈혈",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "정규승인",
    notes: "변경승인 - 지중해빈혈 적응증 추가",
    fdaUrl: "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-oral-treatment-anemia-thalassemia-inherited-blood-disorder",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-23",
    ndaBlaNumber: "BLA 761577",
    applicationNo: "761577",
    applicationType: "BLA",
    brandName: "YARTEMLEA",
    activeIngredient: "narsoplimab-wuug",
    sponsor: "Omeros Corporation",
    indicationFull: "조혈모세포이식 관련 혈전성미세혈관병증 2세 이상 소아 및 성인 환자 치료",
    therapeuticArea: "혈액내과 - TA-TMA",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: true,
    approvalType: "정규승인",
    notes: "FDA 최초 승인 MASP-2 억제제, Breakthrough Therapy 및 Orphan Drug 지정",
    fdaUrl: "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-treat-serious-complication-stem-cell-transplant",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-30",
    ndaBlaNumber: "NDA 220152",
    applicationNo: "220152",
    applicationType: "NDA",
    brandName: "NEREUS",
    activeIngredient: "tradipitant",
    sponsor: "Vanda Pharmaceuticals",
    indicationFull: "성인 멀미 예방",
    therapeuticArea: "신경과 - 멀미",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: false,
    approvalType: "정규승인",
    notes: "FDA 최초 승인 NK-1 수용체 길항제 (멀미 적응증)",
    fdaUrl: "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-tradipitant-prevention-motion-sickness-adults",
  },
];

export const summaryStats = {
  total: 21,
  oncology: 9,
  nonOncology: 12,
  biosimilar: 3,
  novelDrug: 9,
  novelOncology: 0,
  novelNonOncology: 9,
  orphanDrug: 11,
  orphanOncology: 6,
  orphanNonOncology: 5,
};

export const therapeuticAreaData = [
  { name: "다발골수종", value: 2, category: "항암제" },
  { name: "림프종", value: 2, category: "항암제" },
  { name: "전립선암", value: 2, category: "항암제" },
  { name: "유방암", value: 1, category: "항암제" },
  { name: "폐암", value: 1, category: "항암제" },
  { name: "골전이", value: 1, category: "항암제" },
  { name: "대사질환", value: 1, category: "소아과" },
  { name: "신경복구", value: 1, category: "신경과" },
  { name: "유전자치료", value: 1, category: "면역학" },
  { name: "부정맥", value: 1, category: "심장내과" },
  { name: "성매개감염병", value: 1, category: "감염내과" },
  { name: "천식", value: 1, category: "호흡기내과" },
  { name: "안과", value: 1, category: "안과" },
  { name: "심근병증", value: 1, category: "심장내과" },
  { name: "골다공증", value: 1, category: "내분비내과" },
  { name: "지중해빈혈", value: 1, category: "혈액내과" },
  { name: "TA-TMA", value: 1, category: "혈액내과" },
  { name: "멀미", value: 1, category: "신경과" },
];

export const approvalTypeData = [
  { name: "정규승인", value: 21 },
  { name: "신속승인", value: 0 },
];

export const drugCategoryData = [
  { name: "항암제", value: 9 },
  { name: "비항암제", value: 12 },
];

export const specialDesignations = [
  { name: "희귀의약품", value: 11, percentage: 52 },
  { name: "신약", value: 9, percentage: 43 },
  { name: "바이오시밀러", value: 3, percentage: 14 },
];
